FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND: Form 990, tax year 2024
View the entire original 990 at ProPublica ↗
- Organization
- FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND (EIN 98-0407553)
- Tax period
- 2024-01-01 to 2024-12-31
- Filed
- 2025-11-17
- IRS object ID
- 202523219349318337
- Schema version
- 2024v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2025-11-17T15:15:35+00:00 | ReturnTs |
| Tax Period End | 2024-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 346565596 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERNST & YOUNG US LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | ONE MANHATTAN WEST | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 100018604 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2024-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 980407553 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 0000000001 | PhoneNum |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | CHEMIN DU POMMIER 40 | AddressLine1Txt |
| City | GRANDSACONNEX | CityNm |
| Country | SZ | CountryCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DARRYL ENGLISH | PersonNm |
| Person Title | head of finance | PersonTitleTxt |
| Signature | 2025-11-17 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | Yucen Zhong | PreparerPersonNm |
| PTIN | P01593150 | PTIN |
| Phone | 2127733000 | PhoneNum |
| Preparation | 2025-11-17 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2024 | TaxYr |
| Build TS | 2025-03-06 01:10:19Z | BuildTS |
Form 990 IRS990
Doing Business As Name DoingBusinessAsName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FIND | BusinessNameLine1Txt |
Principal Ofcr Business Name PrincipalOfcrBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | DAYO ADETIFA | BusinessNameLine1Txt |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | CHEMIN DU POMMIER 40 | AddressLine1Txt |
| City | GRANDSACONNEX | CityNm |
| Country | SZ | CountryCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $49,306,331 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.FINDDX.ORG | WebsiteAddressTxt |
| Type Of Organization Assoc | Yes (X) | TypeOfOrganizationAssocInd |
| Formation | 2003 | FormationYr |
| Legal Domicile Country | SZ | LegalDomicileCountryCd |
| Activity Or Mission | THE DEVELOPMENT AND IMPLEMENTATION OF NEW, LOW COST DIAGNOSTICS FOR INFECTIOUS DISEASES FOR USE IN LOW-RESOURCE AREAS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 9 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 9 | VotingMembersIndependentCnt |
| Total Employee | 227 | TotalEmployeeCnt |
| Total Volunteers | 3 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $86,961,801 | PYContributionsGrantsAmt |
| CY Contributions Grants | $46,591,810 | CYContributionsGrantsAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $3,411,063 | PYInvestmentIncomeAmt |
| CY Investment Income | $2,412,155 | CYInvestmentIncomeAmt |
| PY Other Revenue | $239,613 | PYOtherRevenueAmt |
| CY Other Revenue | $302,366 | CYOtherRevenueAmt |
| PY Total Revenue | $90,612,477 | PYTotalRevenueAmt |
| CY Total Revenue | $49,306,331 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $35,829,203 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $12,782,246 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $32,721,353 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $20,548,195 | CYSalariesCompEmpBnftPaidAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $696,099 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $27,566,683 | PYOtherExpensesAmt |
| CY Other Expenses | $23,498,205 | CYOtherExpensesAmt |
| PY Total Expenses | $96,117,239 | PYTotalExpensesAmt |
| CY Total Expenses | $56,828,646 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$5,504,762 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$7,522,315 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $81,417,302 | TotalAssetsBOYAmt |
| Total Assets EOY | $51,274,531 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $65,254,547 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $42,634,091 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $16,162,755 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $8,640,440 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $13,927,035 | ExpenseAmt |
| Grant | $6,601,315 | GrantAmt |
| Desc | See schedule O | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $5,232,718 | ExpenseAmt |
| Grant | $422,632 | GrantAmt |
| Desc | See schedule O | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $4,890,020 | ExpenseAmt |
| Grant | $627,673 | GrantAmt |
| Desc | See schedule O | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $22,071,233 | ExpenseAmt |
| Grant | $5,130,626 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $22,071,233 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $5,130,626 | TotalOtherProgSrvcGrantAmt |
| Total Program Service Expenses | $46,121,006 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | false | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | false | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | false | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | false | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | false | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (true) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (true) | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | false | ProfessionalFundraisingInd |
| Fundraising Activities | false | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | false | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Escrow Account | false | EscrowAccountInd |
| On Behalf Of Issuer | false | OnBehalfOfIssuerInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | false | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | false | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (true) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (true) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 0 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 227 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | false | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | false | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | false | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 9 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 9 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | false | MembersOrStockholdersInd |
| Election Of Board Members | false | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | false | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Policies Reference Chapters | false | PoliciesReferenceChaptersInd |
| Form990 Provided To Gvrn Body | false | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| Written Policy Or Procedure | false | WrittenPolicyOrProcedureInd |
| Own Website | Yes (X) | OwnWebsiteInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Sabri Ait-Kheira | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 0000000001 | PhoneNum |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | CHEMIN DU POMMIER 40 | AddressLine1Txt |
| City | GRANDSACONNEX | CityNm |
| Country | SZ | CountryCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (26 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd |
|---|---|---|---|---|---|---|---|---|---|---|
| AYOADE ALAKIJA | ||||||||||
| CHAIRMAN OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| DAVID HEYMANN | ||||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| FRUTIGER CHRISTIAN | ||||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| KAMINENI SHOBANA | ||||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| MARCEL TANNER | ||||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| MICHELE COSTAFORLAZ | ||||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| PRECIOUS MATSOSO | ||||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| RICK ARTHUR BRIGHT | ||||||||||
| MEMBER OF THE BOARD (THRU 8/2024) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| SOUMYA SWAMINATHAN | ||||||||||
| MEMBER OF THE BOARD (THRU 8/2024) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | ||||
| CASSANDRA KELLY-CIRINO | ||||||||||
| VP, HEALTH PROGRAMMES (thru 8/24) | 40.0 | 0.0 | $191,471 | $0 | $44,933 | Yes (X) | ||||
| DAYO ADETIFA | ||||||||||
| CHIEF TRANSFORMATION OFFICER/CEO | 40.0 | 0.0 | $138,966 | $0 | $34,621 | Yes (X) | ||||
| MARTA FERNANDEZ SUAREZ | ||||||||||
| CHIEF TECHNOLOGY OFFICER (thru 10/24) | 40.0 | 0.0 | $285,980 | $0 | $70,585 | Yes (X) | ||||
| NORMA TORRES | ||||||||||
| CHIEF OPERATING OFFICER (thru 5/24) | 40.0 | 0.0 | $215,973 | $0 | $13,980 | Yes (X) | ||||
| SERGIO CARMONA | ||||||||||
| CHIEF MEDICAL OFFICER (thru 9/24) | 40.0 | 0.0 | $284,240 | $0 | $59,142 | Yes (X) | ||||
| SHARON SAACKS | ||||||||||
| SENIOR DIRECTOR, PROGRAMME OPERATIONS (thru 7/24) | 40.0 | 0.0 | $230,858 | $0 | $38,285 | Yes (X) | ||||
| WILLIAM RODRIGUEZ | ||||||||||
| CHIEF EXECUTIVE OFFICER (thru 6/24) | 40.0 | 0.0 | $197,568 | $0 | $25,483 | Yes (X) | ||||
| WILLO BROCK | ||||||||||
| EXECUTIVE VP, EXTERNAL AFFAIRS (thru 6/24) | 40.0 | 0.0 | $163,705 | $0 | $0 | Yes (X) | ||||
| DARRYL ENGLISH | ||||||||||
| DEPUTY DIRECTOR, FINANCE (THRU 11/24) | 40.0 | 0.0 | $342,536 | $0 | $71,485 | Yes (X) | ||||
| KEVIN TETTEH | ||||||||||
| DIRECTOR, MALARIA FEVER PROGRAMME | 40.0 | 0.0 | $181,958 | $0 | $42,996 | Yes (X) | ||||
| SANJAY SARIN | ||||||||||
| VP, ACCESS (thru 10/24) | 40.0 | 0.0 | $232,372 | $0 | $0 | Yes (X) | ||||
| BEATRICE MOUTON | ||||||||||
| DIRECTOR, HUMAN RESOURCES | 40.0 | 0.0 | $260,701 | $0 | $52,305 | Yes (X) | ||||
| BROOKE NICHOLS | ||||||||||
| SENIOR DIRECTOR, IMPACT | 40.0 | 0.0 | $265,429 | $0 | $31,260 | Yes (X) | ||||
| MARIA CECILIA FERREYRA ARELLANO | ||||||||||
| Director of AMR Programme | 40.0 | 0.0 | $213,012 | $0 | $37,012 | Yes (X) | ||||
| MORTEN RUHWALD | ||||||||||
| DIRECTOR, TUBERCULOSIS PROGRAMME | 40.0 | 0.0 | $244,800 | $0 | $53,973 | Yes (X) | ||||
| SHAUKHAT ALI KHAN | ||||||||||
| Director Strategic Information | 40.0 | 0.0 | $235,091 | $0 | $54,490 | Yes (X) | ||||
| Louisa Chaubert | ||||||||||
| DIRECTOR OF FINANCE (THRU 12/23) | 0.0 | 0.0 | $95,808 | $0 | $7,635 | Yes (X) | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,780,468 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $638,185 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 123 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (true) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | Address Line2ContractorAddress/ForeignAddress/AddressLine2Txt | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd | ServicesServicesDesc | CompensationCompensationAmt | CityContractorAddress/ForeignAddress/CityNm |
|---|---|---|---|---|---|---|
| WORLD HEALTH ORGANIZATION | ||||||
| 20 AVENUE APPIA | GENEVA 27 | OC | 271221 | PUBLIC-HEALTH TECHNICAL SUPPORT | $7,000,000 | |
| INSTITUTE PASTEUR OF DAKAR | ||||||
| 36 AVENUE PASTEUR | OC | BP220 | RESEARCH AND LABORATORY DIAGNOSTICS | $4,537,400 | DAKAR | |
| AIRPLUS INTERNATIONAL | ||||||
| AG OBSTGARTENSTRASSE 27 | KLOTEN | OC | 8302 | FLIGHT ARRANGMENT SERVICES | $1,289,682 | |
| GLOBAL FUND GLOBAL HEALTH CAMPUS | ||||||
| CHEMIN DU POMMIER 40 | OC | 1218 | OFFICE SPACE PROVIDER | $742,311 | GENEVA | |
| INTERHYVE SARL | ||||||
| AVENUE BLANC 53 | GENEVA | OC | CH1202 | IT SUPPORT SERVICES | $601,887 | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 105 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $20,189,970 | GovernmentGrantsAmt |
| All Other Contributions | $26,401,840 | AllOtherContributionsAmt |
| Total Contributions | $46,591,810 | TotalContributionsAmt |
Total Oth Program Service Rev TotalOthProgramServiceRevGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $0 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $2,412,155 | TotalRevenueColumnAmt |
| Exclusion | $2,412,155 | ExclusionAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
| Personal | $0 | PersonalAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $0 | SecuritiesAmt |
| Other | $0 | OtherAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| commission on tax deduction | 900099 | $27,171 | $27,171 |
| Other Income | 900099 | $275,195 | $275,195 |
Miscellaneous Revenue MiscellaneousRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $302,366 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $49,306,331 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $2,714,521 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $977,323 | TotalAmt |
| Program Services | $977,323 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,804,923 | TotalAmt |
| Program Services | $11,804,923 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,867,137 | TotalAmt |
| Program Services | $1,690,617 | ProgramServicesAmt |
| Management And General | $997,484 | ManagementAndGeneralAmt |
| Fundraising | $179,036 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,140,314 | TotalAmt |
| Program Services | $11,983,608 | ProgramServicesAmt |
| Management And General | $1,911,358 | ManagementAndGeneralAmt |
| Fundraising | $245,348 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,366,163 | TotalAmt |
| Program Services | $1,058,410 | ProgramServicesAmt |
| Management And General | $287,746 | ManagementAndGeneralAmt |
| Fundraising | $20,007 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $732,173 | TotalAmt |
| Program Services | $481,998 | ProgramServicesAmt |
| Management And General | $250,175 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,442,408 | TotalAmt |
| Program Services | $1,142,324 | ProgramServicesAmt |
| Management And General | $276,543 | ManagementAndGeneralAmt |
| Fundraising | $23,541 | FundraisingAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $274,641 | TotalAmt |
| Program Services | $144,889 | ProgramServicesAmt |
| Management And General | $129,752 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $806,130 | TotalAmt |
| Program Services | $37,198 | ProgramServicesAmt |
| Management And General | $768,932 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $464,632 | TotalAmt |
| Program Services | $97,683 | ProgramServicesAmt |
| Management And General | $366,949 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $439,254 | TotalAmt |
| Program Services | $392,361 | ProgramServicesAmt |
| Management And General | $46,893 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,779,194 | TotalAmt |
| Program Services | $1,024,796 | ProgramServicesAmt |
| Management And General | $754,398 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,400,807 | TotalAmt |
| Program Services | $10,118 | ProgramServicesAmt |
| Management And General | $1,390,689 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,683,118 | TotalAmt |
| Program Services | $1,842,613 | ProgramServicesAmt |
| Management And General | $812,395 | ManagementAndGeneralAmt |
| Fundraising | $28,110 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $567,402 | TotalAmt |
| Program Services | $465,227 | ProgramServicesAmt |
| Management And General | $102,175 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $35,903 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $35,903 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| Project contractor | $13,202,348 | $11,978,946 | $1,023,345 | $200,057 |
| EQUIPMENT & SUPPLIES | $1,169,633 | $1,000,991 | $168,642 | |
| foreign exchange losses | $680,893 | $0 | $680,893 | |
| TRANSLATION & SPONSORSHIP | -$5,750 | -$13,019 | $7,269 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $56,828,646 | TotalAmt |
| Program Services | $46,121,006 | ProgramServicesAmt |
| Management And General | $10,011,541 | ManagementAndGeneralAmt |
| Fundraising | $696,099 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,290,319 | BOYAmt |
| EOY | $30,745,582 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $59,797,621 | BOYAmt |
| EOY | $9,422,473 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,220,098 | BOYAmt |
| EOY | $8,838,243 | EOYAmt |
Receivables From Officers Etc ReceivablesFromOfficersEtcGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,814,846 | BOYAmt |
| EOY | $2,274,612 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $6,989 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $0 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,989 | BOYAmt |
| EOY | $6,989 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Intangible Assets IntangibleAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $287,429 | BOYAmt |
| EOY | -$13,368 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $81,417,302 | BOYAmt |
| EOY | $51,274,531 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $11,866,468 | BOYAmt |
| EOY | $7,587,172 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $53,388,079 | BOYAmt |
| EOY | $35,046,919 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Escrow Account Liability EscrowAccountLiabilityGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Loans From Officers Directors LoansFromOfficersDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $65,254,547 | BOYAmt |
| EOY | $42,634,091 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,660,263 | BOYAmt |
| EOY | $6,645,902 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,502,492 | BOYAmt |
| EOY | $1,994,538 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,162,755 | BOYAmt |
| EOY | $8,640,440 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $81,417,302 | BOYAmt |
| EOY | $51,274,531 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$7,522,315 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $97,561,319 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $108,984,293 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $142,991,509 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $86,961,801 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $46,591,811 | CurrentTaxYearAmt |
| Total | $483,090,733 | TotalAmt |
Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $97,561,319 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $108,984,293 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $142,991,509 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $86,961,801 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $46,591,811 | CurrentTaxYearAmt |
| Total | $483,090,733 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $23,090,693 | SubstantialContributorsTotAmt |
| Public Support Total170 | $460,000,040 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $189,810 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $624,209 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $961,319 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $3,411,063 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $2,412,155 | CurrentTaxYearAmt |
| Total | $7,598,556 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $461,449 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $423,638 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $295,241 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $239,613 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $302,366 | CurrentTaxYearAmt |
| Total | $1,722,307 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $492,411,596 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $0 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.93418 | PublicSupportCY170Pct |
| Public Support PY170 | 0.92233 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Schedule A, Part II COLUMNS A-D | THE SUPPORT AMOUNTS REPORTED IN COLUMNS A THROUGH D ARE REPORTED ON A CONSOLIDATED BASIS. |
| Schedule A, Part II, Line 10 Other Income | DESCRIPTION - COMMISSION ON TAX DEDUCTION, COLUMN A - 461449.0, COLUMN B - 423638.0, COLUMN C - 295241.0, COLUMN D - 239613.0, COLUMN E - 27171.0, COLUMN F - 1447112.0; DESCRIPTION - OTHER INCOME, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - , COLUMN E - 275195.0, COLUMN F - 275195.0; |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $6,989 | OtherCostOrOtherBasisAmt |
| Book Value | $6,989 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $6,989 | TotalBookValueLandBuildingsAmt |
| Total Rev Etc Audited Fincl Stmt | $49,306,331 | TotalRevEtcAuditedFinclStmtAmt |
| Other Revenue | $0 | OtherRevenueAmt |
| Revenue Not Reported | $0 | RevenueNotReportedAmt |
| Revenue Subtotal | $49,306,331 | RevenueSubtotalAmt |
| Other Revenues Not Included | $0 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $0 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $49,306,331 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $56,828,646 | TotExpnsEtcAuditedFinclStmtAmt |
| Other Expenses Included | $0 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $0 | ExpensesNotReportedAmt |
| Expenses Subtotal | $56,828,646 | ExpensesSubtotalAmt |
| Other Expenses Not Included | $0 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $56,828,646 | TotalExpensesPerForm990Amt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (9 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| Sub-Saharan Africa | 1 | 24 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $11,437,079 |
| South Asia | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $2,838,911 |
| East Asia and the Pacific | 1 | 7 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $2,516,239 |
| Europe (Including Iceland and Greenland) | 1 | 179 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $34,190,111 |
| South America | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $718,880 |
| North America (Canada & Mexico only) | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $536,256 |
| Russia and Neighboring States | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $78,098 |
| Middle East and North Africa | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $191,790 |
| Central America and the Caribbean | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $40,483 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 3 | SubtotalOfficesCnt |
| Subtotal Employees | 210 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 3 | TotalOfficeCnt |
| Total Employee | 210 | TotalEmployeeCnt |
| Subtotal Spent | $52,547,847 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $52,547,847 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (7 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Description Of Non Cash AsstDescriptionOfNonCashAsstTxt | Valuation Method UsedValuationMethodUsedDesc |
|---|---|---|---|---|---|
| Sub-Saharan Africa | DIAGNOSTICS | $5,538,205 | ELEC FD TRAN | N/A | N/A |
| South Asia | DIAGNOSTICS | $204,033 | ELEC FD TRAN | N/A | N/A |
| East Asia and the Pacific | DIAGNOSTICS | $866,217 | ELEC FD TRAN | N/A | N/A |
| Europe (Including Iceland and Greenland) | DIAGNOSTICS | $4,581,949 | ELEC FD TRAN | N/A | N/A |
| South America | DIAGNOSTICS | $532,607 | ELEC FD TRAN | N/A | N/A |
| Russia and Neighboring States | DIAGNOSTICS | $54,879 | ELEC FD TRAN | N/A | N/A |
| Middle East and North Africa | DIAGNOSTICS | $27,033 | ELEC FD TRAN | N/A | N/A |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 52 | Total501c3OrgCnt |
| Total Other Org | 57 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds | CONTRACTS ARE GIVEN FOR RESEARCH AND DEVELOPMENT OF NEW TOOLS FOR THE DIAGNOSIS OF INFECTIOUS DISEASES. EXCEPT FOR THE INITIAL ADVANCE PAYMENTS, PAYMENTS ARE CONDITIONAL UPON ACHIEVEMENT OF MILESTONES OR DELIVERABLES THROUGH THE PERIOD OF THE CONTRACT AS EVIDENCED IN CONTRACTUALLY SPECIFIED REPORTS. IN ADDITION TO THE REGULAR REPORTS, PROGRAM MANAGERS MONITOR PROGRESS WITH REGULAR COMMUNICATIONS AND PHYSICAL AND VIRTUAL SITE VISITS. FINALLY, MOST MAJOR GRANTS ARE SUBJECT TO ANNUAL DONOR AUDITS WHICH ARE IN ADDITION TO THE STATUTORY AUDIT. |
| Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements | CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; RUSSIA AND NEIGHBORING STATES-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual |
| Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements | EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; RUSSIA AND NEIGHBORING STATES-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (10 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| American Society of Tropical Med | ||||||||
| ONE PARKVIEW PLAZA SUITE 800 | Oakbrook Terrace | IL | 60181 | 570408245 | 501(C)(3) | $50,000 | PUBLICATION OF JOURNAL SUPPLEMENT | |
| Clinton Health Access Initiative Inc | ||||||||
| 383 DORCHESTER AV | BOSTON | MA | 02127 | $288,213 | TO SUPPORT TB ELIMINATION EFFORTS | SUITE 400 | ||
| DIAGNOSTIC CONSULTING NETWORK | ||||||||
| 6354 CORTE DEL ABETO | CARLSBAD | CA | 92011 | 205531959 | $410,848 | DEVELOPMENT OF DIAGNOTIC TESTS | STE B | |
| Drugs & Diagnostics for Tropical Diseases | ||||||||
| 4898 RONSON CT | SAN DIEGO | CA | 92111 | $10,011 | RAPID DIAGNOSTIC TESTING FOR BURULI ULCER | SUITE C | ||
| DIMAGI INC | ||||||||
| 585 MASSACHUSETTS | Cambridge | MA | 02139 | $30,457 | PRODUCTION OF MOBILE PHONE APPS THAT COLLECTS DATA FROM RAPID VITRO DIAGNOSTIC TEST AND THAT CAN AID AN RDT USER IN INTERPRETING THE TEST RESULTS | AVENUE SUITE 3 | ||
| Georgetown University Center for Global Health Practice and Impact | ||||||||
| 37TH AND 0 STREETS | WASHINGTON | DC | 20057 | 530196603 | 501(C)(3) | $24,922 | DRIVING EQUITABLE ACCESS TO TESTING IN LMICS THROUGH EFFECTIVE AND AFFORDABLE TESTS AND INFRASTRUCTURE | SUITE 208 |
| HARVARD COLLEGE | ||||||||
| 1350 MASSACHUSETTS AVENUE | cambridge | MA | 02138 | 042103580 | 501(C)(3) | $9,802 | PROJECT AGREEMENT WITH HARVARD FOR SEQ&TREAT MUTATIONS CATALOGUE WORK | Suite 727E |
| Program appropriate Tech in Health | ||||||||
| 437 N 34TH STREET | SEATTLE | WA | 98103 | 911157127 | 501(C)(3) | $40,119 | GENOMICS TRAININGS. SUPPORTING THE AFRICA CDC WORKFORCE DEVELOPMENT EFFORT FOR PATHOGEN GENOMIC SURVEILLANCE | |
| QUANTIGEN | ||||||||
| 7340 CROSSING PLACE | FISHER | IN | 46038 | $40,570 | ACCELERATING TOOLS TO DRIVE TUBERCULOSIS DETECTION | SUITE 200 | ||
| UNIVERSITY OF NORTH CAROLINA | ||||||||
| 104 AIRPORT DRIVE | Chapel Hill | NC | 275991350 | 566001393 | 501(C)(3) | $506,168 | LABORATORY STRENGTHENING TO SUPPORT CLINICAL CARE AND RESEARCH | SUITE 2200 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 5 | Total501c3OrgCnt |
| Total Other Org | 5 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds | FormAndLineReferenceDesc |
| Explanation | CONTRACTS ARE GIVEN FOR RESEARCH AND DEVELOPMENT OF NEW TOOLS FOR THE DIAGNOSIS OF INFECTIOUS DISEASES. EXCEPT FOR THE INITIAL ADVANCE PAYMENTS, PAYMENTS ARE CONDITIONAL UPON ACHIEVEMENT OF MILESTONES OR DELIVERABLES THROUGH THE PERIOD OF THE CONTRACT AS EVIDENCED IN CONTRACTUALLY SPECIFIED REPORTS. IN ADDITION TO THE REGULAR REPORTS, PROGRAM MANAGERS MONITOR PROGRESS WITH REGULAR COMMUNICATIONS AND PHYSICAL AND VIRTUAL SITE VISITS. FINALLY, MOST MAJOR GRANTS ARE SUBJECT TO ANNUAL DONOR AUDITS WHICH ARE IN ADDITION TO THE STATUTORY AUDIT. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (true) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | false | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | false | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (17 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Louisa Chaubert | ||||||||||||||
| DIRECTOR OF FINANCE (THRU 12/23) | $0 | $0 | $0 | $0 | $95,808 | $0 | $7,635 | $0 | $0 | $0 | $103,443 | $0 | $0 | $0 |
| WILLIAM RODRIGUEZ | ||||||||||||||
| CHIEF EXECUTIVE OFFICER (thru 6/24) | $197,568 | $0 | $0 | $0 | $0 | $0 | $25,483 | $0 | $0 | $0 | $223,051 | $0 | $0 | $0 |
| CASSANDRA KELLY-CIRINO | ||||||||||||||
| VP, HEALTH PROGRAMMES (thru 8/24) | $191,471 | $0 | $0 | $0 | $0 | $0 | $38,430 | $0 | $6,503 | $0 | $236,404 | $0 | $0 | $0 |
| MARTA FERNANDEZ SUAREZ | ||||||||||||||
| CHIEF TECHNOLOGY OFFICER (thru 10/24) | $285,980 | $0 | $0 | $0 | $0 | $0 | $56,899 | $0 | $13,686 | $0 | $356,565 | $0 | $0 | $0 |
| NORMA TORRES | ||||||||||||||
| CHIEF OPERATING OFFICER (thru 5/24) | $215,973 | $0 | $0 | $0 | $0 | $0 | $13,980 | $0 | $0 | $0 | $229,953 | $0 | $0 | $0 |
| SERGIO CARMONA | ||||||||||||||
| CHIEF MEDICAL OFFICER (thru 9/24) | $254,041 | $0 | $30,199 | $0 | $0 | $0 | $54,619 | $0 | $4,523 | $0 | $343,382 | $0 | $0 | $0 |
| SHARON SAACKS | ||||||||||||||
| SENIOR DIRECTOR, PROGRAMME OPERATIONS (thru 7/24) | $145,852 | $0 | $0 | $0 | $85,006 | $0 | $38,285 | $0 | $0 | $0 | $269,143 | $0 | $0 | $0 |
| WILLO BROCK | ||||||||||||||
| EXECUTIVE VP, EXTERNAL AFFAIRS (thru 6/24) | $163,705 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $163,705 | $0 | $0 | $0 |
| DAYO ADETIFA | ||||||||||||||
| CHIEF TRANSFORMATION OFFICER/CEO | $138,966 | $0 | $0 | $0 | $0 | $0 | $34,621 | $0 | $0 | $0 | $173,587 | $0 | $0 | $0 |
| SANJAY SARIN | ||||||||||||||
| VP, ACCESS (thru 10/24) | $232,372 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $232,372 | $0 | $0 | $0 |
| KEVIN TETTEH | ||||||||||||||
| DIRECTOR, MALARIA FEVER PROGRAMME | $181,958 | $0 | $0 | $0 | $0 | $0 | $42,996 | $0 | $0 | $0 | $224,954 | $0 | $0 | $0 |
| DARRYL ENGLISH | ||||||||||||||
| DEPUTY DIRECTOR, FINANCE (THRU 11/24) | $342,536 | $0 | $0 | $0 | $0 | $0 | $71,485 | $0 | $0 | $0 | $414,021 | $0 | $0 | $0 |
| BEATRICE MOUTON | ||||||||||||||
| DIRECTOR, HUMAN RESOURCES | $260,701 | $0 | $0 | $0 | $0 | $0 | $44,367 | $0 | $7,938 | $0 | $313,006 | $0 | $0 | $0 |
| BROOKE NICHOLS | ||||||||||||||
| SENIOR DIRECTOR, IMPACT | $265,429 | $0 | $0 | $0 | $0 | $0 | $31,260 | $0 | $0 | $0 | $296,689 | $0 | $0 | $0 |
| MORTEN RUHWALD | ||||||||||||||
| DIRECTOR, TUBERCULOSIS PROGRAMME | $244,800 | $0 | $0 | $0 | $0 | $0 | $44,029 | $0 | $9,944 | $0 | $298,773 | $0 | $0 | $0 |
| MARIA CECILIA FERREYRA ARELLANO | ||||||||||||||
| Director of AMR Programme | $213,012 | $0 | $0 | $0 | $0 | $0 | $30,675 | $0 | $6,337 | $0 | $250,024 | $0 | $0 | $0 |
| SHAUKHAT ALI KHAN | ||||||||||||||
| Director Strategic Information | $235,091 | $0 | $0 | $0 | $0 | $0 | $44,098 | $0 | $10,392 | $0 | $289,581 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule J, Part III | FormAndLineReferenceDesc |
| Explanation | The following individuals received severance payments in 2024: -Sharon Saacks received a severance payment of $85,006 in 2024. -Louisa Chaubert received a severance payment of $95,808 in 2024. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (13 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Form 990, Part III, Line 4a Technology & Development department | (EXPENSES $13,927,035 INCLUDING GRANTS OF $6,601,315)(REVENUE $0) In 2024, FIND's Technology & Development Department continued to advance global health through innovative diagnostics, focusing on expanding access, digital transformation, and the development of next-generation solutions. The department's activities were aligned with FIND's mission to improve health outcomes in low- and middle-income countries (LMICs) by accelerating the availability and adoption of high-quality diagnostic tools. Accelerate access to SARSCOV-2 AgRDTs for Professional Use with manufacturing expansion: FIND supported access to COVID-19 antigen rapid diagnostic tests (AgRDTs) in resource-limited countries by fostering regional manufacturing partnerships. In 2024, the focus was on transferring HIV test technology and building manufacturing capacity with African-based manufacturers, strengthening local production and sustainability. These efforts aimed to ensure a resilient supply chain and reduce dependency on imports. Point Of Care Molecular Diagnostic (POC MDx): FIND invested in four innovative technologies to deliver true and near point-of-care solutions for respiratory panel testing. These platforms were designed to provide rapid, accurate diagnostics at the community level, enabling timely treatment and improved patient outcomes in LMICs. In addition, FIND has conducted an in-depth investigation and assessment of true-POC MDx that led to the launch of feasibility studies on seven small, portable, innovative POC molecular devices. COVID-19 Digital Validation Platform: Building on previous work in computer-aided detection (CAD) for tuberculosis, FIND evaluated digital diagnostics for COVID-19, positioning itself as a leader in digital diagnostic evaluation for the global health community. Technology landscape and DxConnect Test Directory: A core enabler of FIND impact is its ability to generate and disseminate high-quality, open-access IVD technology data that informs decision-making across the diagnostic ecosystem. Our DxConnect Test Directory provides competitive intelligence and detailed information on diagnostic tests and platforms that improve transparency, supports procurement planning, and facilitate innovation. This resource is increasingly used by donors, implementers, and manufacturers to guide strategic investments and product development. FIND has conducted more than 20 technology landscapes covering areas such as antimicrobial resistance, neglected tropical diseases, outbreaks, women's health, and non-communicable diseases. Seq&Treat: FIND accelerated the introduction and adoption of commercial targeted sequencing for the diagnosis of drug-resistant TB (DR-TB). Key 2024 achievements included clinical trials in India, South Africa, and Georgia to support WHO guidance; establishment of a WHO clinical knowledge base (TB-KB) for global sequencing data; proof-of-principle delivery models in India, Indonesia, South Africa, and Brazil; and efforts to address access barriers through pricing collaboration, market mapping, and knowledge sharing. Supporting the development, implementation and evaluation of integrated digital screening tools, and systems for routine collection of syndromic data, at the community level in Rwanda and Kenya: FIND developed and evaluated digital screening approaches at the community level. By integrating disease screening into digital platforms and enhancing contact tracing modules for tuberculosis, FIND demonstrated the feasibility of decentralized community-level screening in Rwanda and Kenya. Shaping the Global Agenda for Genomics: FIND contributed to shaping the global genomics agenda by mapping pathogen genomic sequencing investments and identifying gaps and opportunities for strategic collaboration. This work informed global stakeholders and supported the development of coordinated genomic surveillance strategiesGenomics Costing Tool: FIND co-developed and piloted the Genomics Costing Tool (GCT), a resource to support governments and partners in planning and budgeting for genomic sequencing in public health. In 2024, FIND collaborated with WHO and country partners to validate the tool using tuberculosis genomic sequencing as a use case. The GCT provides a transparent framework for estimating end-to-end costs (from sample collection to data analysis) helping countries and global partners make evidence-based investments in sustainable genomic surveillance systems. Support manufacturers quality standards in Indonesia: Through supporting manufacturer quality standards in Indonesia, FIND provided technical assistance to Indonesian IVD manufacturers to strengthen the quality of locally made diagnostic products for primary healthcare. Activities included training, quality system assessments, and support for regulatory compliance to enhance local manufacturing capabilities. Develop interoperability standards for One Health and newly procured diagnostics to ensure data can inform public-health decision making in Indonesia: FIND developed interoperability standards for One Health and new diagnostics to ensure that data generated from human, animal, and environmental health sources could be integrated and used to inform public health decision-making. This project supported the development of a unified digital health ecosystem. Ensuring equitable access to AI-powered diagnostics in low- and middle-income countries: Equitable access to AI-based diagnostic innovation was advanced in India, Indonesia, and Rwanda through the co-creation of a toolkit for innovating and scaling AI-based diagnostics with partners (e.g., C4IR, Indonesia MoH, and Artpark). The toolkit was applied and tested in in-country workshops to refine its effectiveness in evaluating AI diagnostics and building optimization capacity.Self-testing as a new critical tool to increase access to diagnostics for HIV, hepatitis B, and C virus infections Funded by the NIH, FIND's self-testing initiative advanced the evaluation of multiplex self-tests for HIV, HCV, and HBV. In 2024, FIND conducted performance evaluations as well as feasibility and usability studies among key and vulnerable populations to assess real-world implementation potential. Evidence generated from these studies informs future policy recommendations. FIND also organized a joint technical consultation on multiplex testing with the World Health Organization (WHO), which contributed to the development of WHO's forthcoming 2025 guidelines on multiplex diagnostics. Climate X Diagnostics: FIND's Climate x Diagnostics research and development initiative focused on creating rapid molecular, self-tests, and Ag RDTs suitable for LMICs. The project addressed the need for diagnostics that remain effective under changing operational and epidemiological conditions due to climate change, ensuring resilience in diagnostic services. In summary , the Technology & Development Department's activities in 2024 reflected FIND's commitment to innovation, equity, and sustainability in diagnostics. The department's projects advanced the development, evaluation, and implementation of diagnostic solutions, with a focus on digital transformation, local manufacturing, and equitable access. These efforts contributed to improved health outcomes and strengthened health systems in LMICs. |
| Form 990, Part III, Line 4b Access department | (EXPENSES $5,232,718 INCLUDING GRANTS OF $422,632)(REVENUE $0) In 2024, the FIND Access Department advanced its mission to ensure equitable access to quality diagnostics through strategic initiatives across multiple countries. Our work was organized around four key pillars: Laboratory System Strengthening, Diagnostic Network Optimization (DNO), Non-Communicable Diseases (NCDs), and Training & Capacity Building. This report summarizes the progress and achievements within these thematic areas throughout the year. Laboratory System Strengthening FIND enhanced the quality and sustainability of laboratory services through direct technical assistance. In Bihar, India, the Laboratory System Strengthening project provided support across all 38 districts, mentoring Medical Colleges and implementing quality management systems. This included training over 1,300 staff and conducting 350 site visits, which significantly increased the availability of diagnostic tests. In Indonesia, FIND assisted three referral laboratories in preparing for ISO 15189 accreditation and also led the coordination of the National EDL (NEDL) development in collaboration with the Ministry of Health and other stakeholders. This involved extensive stakeholder engagement and technical working group sessions with relevant Ministry directorates and subject matter experts, contributing to the broader ASEAN Diagnostic Security and Self-Reliance framework. In Bangladesh, technical assistance strengthened TB lab services through SLMTA mentoring at six reference labs, the introduction of a new Laboratory Information Management System, and building national capacity for quality assurance. Diagnostic Network Optimization (DNO) Using geospatial analysis and evidence-based modeling, FIND supported governments in rationalizing diagnostic networks for improved efficiency and access. In Indonesia, the DNO initiative focused on optimizing the TB diagnostic network by identifying optimal platform placement and streamlining sample pathways. In Bangladesh, the project mapped facilities and modeled optimized configurations for TB, HIV, and Malaria services to inform the upcoming National Strategic Plan. In Lao PDR, technical assistance was provided began to develop a national operational plan for an integrated sample transportation system. Globally FIND developed and piloted DxPulse, a new open-source diagnostic network visualization and analysis tool integrated within DHIS2. The pilot in Kenya in 2024, involving two counties, demonstrated its potential for improving data-driven planning and monitoring of diagnostic networks. Non-Communicable Diseases (NCDs) FIND expanded its focus on NCDs by generating critical evidence for policy and investment. The ACCEDE project in South Africa and Kenya, an operational research initiative, is building a local investment case for equitable adoption of continuous glucose monitoring (CGM) in public health systems. The project, co-created with Ministries of Health, combines clinical research and health economic modeling. It also includes a strong capacity-building component, having trained over 670 healthcare professionals across both countries through online and in-person sessions. Training and Capacity Building Building human resource capacity was a key cross-cutting theme. FIND expanded its online training portfolio through the FIND Training Academy. Courses launched in 2024 included "Introduction to Diagnostic Network Optimization (DNO) 2.0," "Introduction to Next-Generation Sequencing and Bioinformatics (INSEQBIN), "Online Training for AMR Scorecard Assessors." The DNO 2.0 course, developed with WHO SERAO, IDC, and ASLM, enrolled 321 learners from 71 countries, while the INSEQBIN course, in partnership with Fondation Merieux, trained 114 learners from 26 countries. In Indonesia, FIND also developed the "Fundamental Training on Essential Diagnostics" curriculum for the Ministry of Health to enhance laboratory workforce capacity in implementing new diagnostic tools and referral systems. |
| Form 990, Part III, Line 4c Tuberculosis (TB) programme | (EXPENSES $4,890,020 INCLUDING GRANTS OF $627,673) (REVENUE $0) TB Programme Activities - 2024 Summary 1. TB Fluorescent LAM Test Development This project focused on advancing fluorescent-based LAM assays to improve diagnostic sensitivity for TB in HIV-positive populations. In 2024, prototype assays were refined and evaluated in controlled laboratory settings. Preliminary data demonstrated enhanced detection rates compared to conventional LAM tests, paving the way for field validation. 2. TPP for Centralised TB Assays The initiative aimed to develop Target Product Profiles (TPPs) for centralised TB diagnostic platforms to guide manufacturers and procurement agencies. During 2024, consensus workshops were held with global stakeholders to finalise specifications for accuracy, throughput, and cost-effectiveness. The resulting TPPs were published and disseminated to inform future product development. 3. TB-CAPT (Close the gap, increase Access, Provide adequate Therapy) TB-CAPT sought to expand access to TB diagnosis and treatment in high-burden countries through integrated service delivery. In 2024, the programme scaled up TB testing and primary health centres and improved linkage-to-care pathways in multiple regions. These efforts resulted in thousands of additional patients initiating timely therapy. Three separate trials were conducted to increase access and diagnosis in symptomatic adults, PLHIV and people with drug-resistant TB. These studies have lead to policy changes and adoption in countries. 4. Predicting the Future: Incipient Tuberculosis (PreFIT) PreFIT aimed to identify biomarkers and predictive models for incipient TB to enable early intervention. Over the year, large cohort studies in South Africa, Mozambique and Uganda were initiated and data analysis frameworks established. Multiple novel tests were evaluated for performance in diagnosing active TB and predicting progression to TB. The primary test evaluated was Cepheid's Xpert Host Response transcriptomic test. 5. Bioneer Accupower RFIA Clinical Evaluation This project evaluated the laboratory analytical and clinical performance of the Bioneer Accupower Rapid Fluorescent Immunoassay for TB detection. In 2024, multi-site trials were completed across diverse epidemiological settings in Peru, Kenya and Ukraine. Specimens have been banked, and a new version of the test will be released in 2025 to complement results. This data will be used to support regulatory submission plans in 2026. 6. FEND for TB (Feasibility of Novel Diagnostics for TB in Endemic Countries) FEND for TB assessed the operational feasibility of introducing novel TB diagnostics in resource-limited settings. During 2024, pilot deployments were conducted in endemic countries, focusing on performance and accuracy of prototype early-stage diagnostics. Over 300 products were assessed through scouting, and over 60 products entered into evaluations in the lab and/or clinic across 5 countries. 7. Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) The R2D2 TB Network aimed to accelerate collaborative research on innovative TB diagnostics. In 2024, the network expanded to include new academic and industry partners and launched joint studies on next-generation assays. These collaborations produced early prototypes and shared data platforms to speed development. FIND supported scouting activities, data coordination for trialing and evidence generation, shared manuscript, and chest xray evaluations. 8. TB Triage Test This project focused on evaluating triage tests for TB to optimise patient flow in primary care settings. In 2024, field studies assessed performance in high-volume clinics and explored integration with digital tools. Results showed improved case detection and reduced diagnostic delays.Primary assays evaluated were the blood-based MBT host proteomic biomarker assay, and the Xpert HR cartrridge. 9. UNITE4TB (Academia and Industry United Innovation and Treatment for TB) UNITE4TB advanced partnerships between academia and industry to accelerate TB treatment innovation. In 2024, the consortium initiated clinical trials for novel drug regimens and strengthened regulatory engagement. These efforts positioned the programme as a key contributor to global treatment pipeline development. FIND's role has been to ensure that diagnostics development keeps pace with drug regimen approvals so that the appropriate tests are available to detect resistance before it emerges. 10. Drive Diagnostics for Tuberculosis The DriveDx4TB project aimed to fast-track deployment of diagnostic platforms in priority geographies. In 2024, procurement frameworks were established and training delivered to local laboratories. This resulted in expanded diagnostic coverage and improved turnaround times for TB testing. 11. Truenat COMBO: Bidirectional Dx for TB and Covid-19, with extensive tongue swab banking COMBO integrated multiplex molecular diagnostics for TB and COVID-19 while creating a biobank of tongue swab samples. In 2024, dual testing protocols were validated and implemented in pilot sites. The biobank now supports ongoing research into non-invasive sampling methods. 12. Optimise Xpert oriented Active Case finding for TB and COVID-19 (XACT-19) XACT-19 focused on optimising active case finding strategies using Xpert platforms for TB and COVID-19. In 2024, community screening campaigns were expanded and operational workflows streamlined. These interventions significantly increased detection rates for both diseases. 13. Next-generation TB LAM Tests This project supported the development of ultra-sensitive LAM assays for TB diagnosis in vulnerable populations. In 2024, candidate tests progressed through analytical validation and early clinical evaluation. Data indicated substantial improvements in sensitivity compared to existing LAM tests. 14. TB Lab Development and Support (India) The programme aimed to strengthen TB laboratory capacity through infrastructure and technical assistance. In 2024, multiple labs received equipment upgrades and staff training on advanced diagnostic techniques. These improvements enhanced quality assurance and reduced turnaround times. 15. Integrated community-based TB prevention and care (India) This initiative delivered integrated TB prevention and care services at the community level in India. In 2024, outreach programmes expanded to rural districts and incorporated digital adherence tools. The approach improved treatment completion rates and community engagement. 16. Dx System Strengthening for TB (India) The project focused on strengthening diagnostic systems in Maharashtra and Bihar to improve TB detection. In 2024, new molecular platforms were installed and workforce capacity enhanced through targeted training. These efforts led to measurable increases in diagnostic throughput. 17. Systematic TB CAD Evaluation for WHO Prequalification, Pediatrics, and People living with HIV (STEP3) STEP3 evaluated computer-aided detection (CAD) tools for TB screening in paediatric populations and people living with HIV. In 2024, multi-country studies generated evidence for WHO prequalification submissions. Data review, analysis and optomisation is ongoing through 2025. It is expected that findings will support CAD as a viable adjunct to radiography in high-risk groups. 18. Mentoring Indonesia's TB labs for ISO 15189 accreditation This project provided mentorship to Indonesian TB laboratories to achieve ISO 15189 accreditation. In 2024, gap assessments were planned. |
| Form 990, Part III, Line 4d Description of other program services | (Expenses $ 22,071,233 including grants of $ 5,130,626)(Revenue $ 0) Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa |
| Form 990, Part V, Line 2a AND PART VII, SECTION A | INDIVIDUALS EMPLOYED BY FIND ARE NOT US RESIDENTS OR US EMPLOYEES. INFORMATION PERTAINING TO THE NUMBER OF EMPLOYEES AND EMPLOYEE COMPENSATION IS PROVIDED USING THE BEST INFORMATION AVAILABLE FROM EQUIVALENT W-2 & W-3 FORMS FOR THE VARIOUS COUNTRIES IN WHICH FIND EMPLOYS INDIVIDUALS. |
| Form 990, Part VI, Line 20 BOOKS IN CARE OF PHONE NUMBER | THE TELEPHONE NUMBER OF THE PERSON WHO POSSESSES THE BOOKS AND RECORDS IS +41 (22) 710 0590 |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM AND REVIEWED BY THE DIRECTOR OF FINANCE. ONCE APPROVED BY THE DIRECTOR OF FINANCE, THE FORM 990 IS ALSO REVIEWED BY THE CEO. ADDITIONALLY, IN 2021, FIND PARTICIPATED IN A BENCHMARKING EXERCISE WITH PEER OF FINANCE, THE FORM 990 IS ALSO REVIEWED BY THE CEO. ADDITIONALLY, IN 2021, FIND PARTICIPATED IN A BENCHMARKING EXERCISE WITH PEER ORGANIZATION TO ENSURE CONSISTENCY OF TREATMENT OF VARIOUS ITEMS ON FORM 990. |
| Form 990, Part VI, Line 12c Conflict of interest policy | FINDS CONFLICT OF INTEREST POLICY REQUIRES DIRECTORS, OFFICERS AND KEY EMPLOYEES, ALL OTHER STAFF MEMBERS, BOARD MEMBERS, CONSULTANTS AND PARTNERS TO DISCLOSE ACTUAL OR POTENTIAL CONFLICTS OF INTEREST WHEN THEY ARISE. THE PERSON OR COMPANY IS ALSO REQUIRED TO RECUSE THEMSELVES FROM ANY DECISION MAKING. |
| Form 990, Part VI, Line 15a Process to establish compensation of top management official | A REVIEW BY AN INDEPENDENT CONSULTANT OF THE CEO'S REMUNERATION PACKAGE WAS DONE BY THE BOARD AND FORMS THE BASIS OF A WRITTEN EMPLOYMENT CONTRACT. REMUNERATION TERMS FOR OFFICERS AND KEY EMPLOYEES ARE BASED ON MARKET RATES FOR SIMILAR POSITIONS IN SPECIFIC LOCATIONS. THE COMPENSATION COMMITTEE. THIS BENCHMARKING IS DONE AGAINST AN INDEPENDENT REPORT WHICH PRESENTS DATA COLLECTED FOR SIMILAR ORGANIZATIONS AND THIS EXERCISE IS DONE EVERY 3 YEARS. SALARIES FOR ALL STAFF ARE AVAILABLE TO THE BOARD AND COMPENSATION COMMITTEE. HOWEVER, THE SALARIES OF THE C-SUITE AND OTHER KEY STAFF ARE APPROVED BY THE COMPENSATION COMMITTEE. |
| Form 990, Part VI, Line 15b Process to establish compensation of other employees | A REVIEW BY AN INDEPENDENT CONSULTANT OF THE CEO'S REMUNERATION PACKAGE WAS DONE BY THE BOARD AND FORMS THE BASIS OF A WRITTEN EMPLOYMENT CONTRACT. REMUNERATION TERMS FOR OFFICERS AND KEY EMPLOYEES ARE BASED ON MARKET RATES FOR SIMILAR POSITIONS IN SPECIFIC LOCATIONS. THE COMPENSATION COMMITTEE. THIS BENCHMARKING IS DONE AGAINST AN INDEPENDENT REPORT WHICH PRESENTS DATA COLLECTED FOR SIMILAR ORGANIZATIONS AND THIS EXERCISE IS DONE EVERY 3 YEARS. SALARIES FOR ALL STAFF ARE AVAILABLE TO THE BOARD AND COMPENSATION COMMITTEE. HOWEVER, THE SALARIES OF THE C-SUITE AND OTHER KEY STAFF ARE APPROVED BY THE COMPENSATION COMMITTEE. |
| Form 990, Part VI, Line 19 Required documents available to the public | UPON REQUEST FIND'S GOVERNING DOCUMENTS (STATUTES AND BY-LAWS) CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE FOR INSPECTION AT FIND'S OFFICES IN GENEVA, SWITZERLAND. |
| Schedule F, Part II, Line 2 | DUE TO THE HIGH VOLUME OF ORGANIZATIONS THAT WERE PROVIDED ASSISTANCE FROM FIND DURING 2024, IT WOULD BE DIFFICULT FOR FIND TO LIST EACH ORGANIZATIONS AND GRANT AMOUNT INDIVIDUALLY ON SCHEDULE F, PART II. THEREFORE, FIND HAS LISTED THE TOTAL AMOUNT OF ASSISTANCE PROVIDED FOR REGION IN 2024. |
| FORM 990 Box E | THE ORGANIZATION'S TELEPHONE NUMBER IS +41 (22) 710 0590. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Province Or StateForeignAddress/ProvinceOrStateNm |
|---|---|---|---|---|---|---|---|---|
| FIND INDIA | ||||||||
| FLAT NO 8 9TH FL 17 BARAKHAM | NEW DELHI | IN | 110001 | PROGRAM SERVICES | IN | FIND SWISS | Yes (true) | |
| FIND DX NPC | ||||||||
| 89 ROODEBLOEM ROAD | WOODSTOCK | SF | PROGRAM SERVICES | SF | FIND SWISS | Yes (true) | CAPE TOWN | |
| FIND DX KENYA | ||||||||
| OFF MBAGATHI RD PO BOX 54840 | NAIROBI | KE | 00200 | PROGRAM SERVICES | KE | FIND SWISS | Yes (true) | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | false | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | false | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | false | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | false | SharingOfFacilitiesInd |
| Paid Employees Sharing | false | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | false | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | Yes (true) | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (2 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| FIND DX KENYA | ||
| R | $314,210 | FMV |
| FIND DX NPC | ||
| R | $807,507 | FMV |